Chronological Index of BioCentury, The Bernstein Report on BioBusiness: Tools & Techniques

• Metabasis' quantum hop

  The pharmaceutical industry rarely uses free energy perturbation-based methods in computer-aided drug design because these methods have low …

  Published on 9/10/2007

• Harnessing sodium channels

  Sodium channels are large voltage-gated transmembrane proteins that play an important role in many physiological processes by …

  Published on 8/27/2007

• Two sides to SIRT1

  In the last few years, companies have started pursuing agonism of SIRT1 as a way of boosting the body's metabolism to treat Type II diabetes, while …

  Published on 8/27/2007

• Dynamic dimerization

  Technology Dynamic dimerization InNexus Biotechnology Inc. chose a well-validated target, CD20, to show that its second generation, conjugated monoclonal antibodies are more potent than first generation, …

  Published on 8/13/2007

• Dysfunction stymies HDL

  Technology Dysfunction stymies HDL Although raising HDL is a major focus for many companies generating small molecule atherosclerosis therapies, the strategy has not yet led to clinical benefit. Researchers from the…

  Published on 8/13/2007

• Expanding the liver repertoire

  Researchers from the University of North Carolina at Chapel Hill reported in the Journal of Experimental Medicine the identification and …

  Published on 8/13/2007

• Caspase cascade

  Technology: Apoptosis shortcut Caspase cascade By targeting procaspase-3, BioLineRx Ltd. believes BL-4030 can bypass upstream elements in the intrinsic and extrinsic apoptosis pathways. In the intrinsic pathway, the…

  Published on 7/30/2007

• Apoptosis shortcut

  Caspase cascade Targeting proteins in the apoptotic pathway can be difficult because the pathway is often rendered nonfunctional by mutations and …

  Published on 7/30/2007

• Early mDIC-ations

  Isis Pharmaceuticals Inc. believes it is the first to show preclinical efficacy with a novel obesity target - mitochondrial dicarboxylate carrier (mDIC…

  Published on 7/9/2007

• Lexicon's lipid-lowering antibody

  Lexicon Pharmaceuticals Inc. published data last week showing that its antibodies against angiopoietin-like protein 4 produce …

  Published on 7/9/2007

• Nuvelo's stealth target

  Ever since Nuvelo Inc. was formed through the merger of Hyseq Pharmaceuticals Inc. and Variagenics Inc. in 2003, the company's clinical focus has …

  Published on 6/18/2007

• What's next for mouse reprogramming

  While a presidential veto looms for the embryonic stem cell legislation that passed the U.S. House of Representatives last week, three …

  Published on 6/11/2007

• Signal snapshots

  Mass spectrometry-based proteomics can reveal protein-protein interactions using large sample sizes and analyzing binding relationships long after a cell …

  Published on 6/4/2007

• Catching up to GM-CSF

  Technology Briefing Catching up to GM-CSF The first hint that blocking GM-CSF might be useful to treat immune system diseases occurred about 15 years ago, when administration of the protein to treat neutropenia in …

  Published on 5/28/2007

• Dutch imaging combine

  Technology Briefing Dutch imaging combine Diagnosing psychiatric disorders is difficult owing to poor understanding of the exact causes and mechanisms underlying them. This not only leads to problematic diagnoses, …

  Published on 5/28/2007

• Target hunting(tin)

  By homing in on the pool of genes encoding proteins that interact with the huntingtin protein, which is implicated in Huntington's disease, researchers have…

  Published on 5/28/2007

• Bacterial power outage

  It has long been suspected that Tibotec BVBA's TMC207 acts by targeting the ATP synthase complex of M. tuberculosis, but the mechanism had not been …

  Published on 5/21/2007

• ALS: Sodden dance

  While it has been known for some time that a mutation in the superoxide dismutase 1 gene plays a role in some cases of amyotrophic lateral sclerosis, …

  Published on 5/14/2007

• Terpene assembly line

  Terpenoids are a class of plant secondary metabolites that include some important pharmacologically active compounds, but they are produced in low …

  Published on 5/14/2007

• Noxxon builds its case

  Noxxon Pharma AG has struggled to raise funds since 2002, but last week it cashed in on a 2006 deal with Pfizer Inc. and recent preclinical …

  Published on 5/7/2007

• Ranking the kinase kingdom

  Likely kinase cancer genes High probability pathways After four years of work, researchers at the Wellcome Trust Sanger Institute and …

  Published on 4/23/2007

• High probability pathways

  Cover Story: Technology: Ranking the kinase kingdom High probability pathways Researchers at the Wellcome Trust Sanger Institute and colleagues ordered pathways by probability of having at least one driver mutation …

  Published on 4/23/2007

• Likely kinase cancer genes

  Cover Story: Technology: Ranking the kinase kingdom Likely kinase cancer genes Top 20 kinase genes ordered by conditional probability of carrying at least one driver mutation. Ranking was determined by statistical …

  Published on 4/23/2007

• Biomarking PTEN

  Researchers from the University of California at Los Angeles and colleagues have identified a biomarker that may prove helpful in selecting likely …

  Published on 4/23/2007

• Upstaging Velcade

  When Millennium Pharmaceuticals Inc. began working on the first proteasome inhibitor to reach the market, Velcade bortezomib, one of the potential issues was …

  Published on 4/23/2007